NeoALLTo Data Supports pCR as End Point in Trials

Published April 10, 2014

NeoALLTo Data Supports pCR as End Point in Trials
… of Breast Medical Oncology at the University of Texas MD Anderson Cancer Center in Houston, said the study was important because it provided further evidence that pCR was “a strong surrogate end point,” one that can be used “to develop new drugs …
Read more on Clinical Oncology News

US stocks rise for the first time in 4 days
Trader James Riley, center, works on the floor of the New York Stock Exchange, Tuesday, April 8, 2014. Stocks were … —Gilead Sciences fell $ 2.22, or 3.1 percent, to $ 70.01 following reports that Express Scripts, the largest U.S. pharmacy benefits …
Read more on Chron.com

More Drug Treatment Centers Houston Information…